1-6 of 6
Qiang Xu, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML)

Daniel A. Pollyea, MD, Martin S. Tallman, MD, Stephane De Botton, Courtney D. DiNardo, MDMSc, Hagop M. Kantarjian, MD, Robert H. Collins, MD, Anthony S. Stein, MD, Qiang Xu, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Eytan M. Stein, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 638.
https://doi.org/10.1182/blood.V130.Suppl_1.638.638
Published: 2017
Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 343.
https://doi.org/10.1182/blood.V128.22.343.343
Published: 2016
Journal Articles

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Yue Gao, PhD, Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Yang, PhD, Katherine Yen, PhD, Sam Agresta, MD, Eyal C. Attar, MD, Jian Chen, PhD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Yan Li, PhD
Journal: Blood
Blood (2015) 126 (23): 2509.
https://doi.org/10.1182/blood.V126.23.2509.2509
Published: 2015
Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Eytan M. Stein, MD, Courtney DiNardo, MD, Jessica K. Altman, MD, Robert Collins, MD, Daniel J. DeAngelo, MD PhD, Hagop M. Kantarjian, MD, Mikkael A. Sekeres, MD MS, Amir T. Fathi, MD, Ian W. Flinn, MD PhD, Arthur E. Frankel, MD, Ross L. Levine, MD, Bruno C. Medeiros, MD, Manish R. Patel, MD, Daniel Pollyea, MD MS, Gail J. Roboz, MD, Richard M. Stone, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Martin S. Tallman, MD, Katherine Yen, PhD, Eyal C. Attar, MD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Stéphane De Botton, MD PhD
Journal: Blood
Blood (2015) 126 (23): 323.
https://doi.org/10.1182/blood.V126.23.323.323
Published: 2015
Journal Articles

Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients

Dana E Rollison, PhD, Kenneth H. Shain, MD PhD, Ji-Hyun Lee, PhD, Shalaka S Hampras, PhD, William Fulp, Kate Fisher, MA, Najla H Al Ali, Eric Padron, MD, Jeffrey Lancet, Qiang Xu, PhD, Robert D. Knight, MD, Alan F. List, MD, William Dalton, PhD MD, Rami Komrokji, MD
Journal: Blood
Blood (2014) 124 (21): 1912.
https://doi.org/10.1182/blood.V124.21.1912.1912
Published: 2014
Journal Articles

Incidence of Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV) Infections and Use of Prophylaxis in Lenalidomide-Treated Multiple Myeloma (MM) Patients (pts): An Analysis of MM Trials

Dianna Gary, BSN, Lilia Weiss, MD, Zhinuan Yu, PhD, Qiang Xu, PhD, Neil Minton, MD, David Gillen, MD, Axel Glasmacher, MD, John Freeman, MSc, BSc, JD
Journal: Blood
Blood (2014) 124 (21): 3451.
https://doi.org/10.1182/blood.V124.21.3451.3451
Published: 2014